Breaking Down Shenyang Xingqi Pharmaceutical Co.,Ltd Financial Health: Key Insights for Investors

Shenyang Xingqi Pharmaceutical Co., Ltd., a National High‑tech Enterprise founded in 1977 and listed on ChiNext on December 8, 2016, stands at the intersection of mission-driven care and measurable performance-employing about 1,500 people to research, produce and sell ophthalmic medications including myopia prevention and control therapies, anti‑infective and anti‑inflammatory drugs, artificial tears and lubricants; the company channels roughly 10% of its revenue into R&D, operates a manufacturing facility aligned with US FDA cGMP and EU GMP standards, and has reinvested over 20 million CNY in health education and community wellness while earning the Silver Medal of the 9th Liaoning Province Governor's Award (2022) and the 20th National Quality Prize (2023) as it pursues a vision to grow into a globally competitive ophthalmic researcher‑manufacturer grounded in perseverance, innovation, responsibility and win‑win values.

Shenyang Xingqi Pharmaceutical Co.,Ltd (300573.SZ) - Intro

• Founded: 1977
• Listing: ChiNext, Shenzhen Stock Exchange - Dec 8, 2016 (300573.SZ)
• Headquarters: Shenyang, Liaoning Province, China
• Employees: ~1,500
• Facility standards: US FDA cGMP & EU GMP design compliance
• Key accolades: Liaoning Governor's Award (Silver, 2022); 20th National Quality Prize (2023)

Mission

• Deliver safe, effective ophthalmic medicines that protect vision and improve life quality.
• Advance accessible myopia prevention and control through evidence-based therapeutics and patient-centered care.
• Maintain manufacturing excellence and regulatory compliance to ensure consistent product quality.

Vision

• Become a global leader in ophthalmic therapeutics, recognized for innovation in myopia control and eye health.
• Create a sustained ecosystem of R&D, manufacturing, and distribution that elevates standards across ophthalmology.

Core Values

• Patient-first: clinical outcomes and safety drive decisions.
• Scientific integrity: rigorous R&D, evidence-based product development.
• Quality excellence: cGMP/EU GMP alignment, continuous improvement.
• Collaboration: partnerships with clinicians, universities and industry stakeholders.
• Accountability: transparent governance and regulatory compliance.

Product Portfolio & Strategic Focus

• Myopia prevention & control: pharmacologic interventions and adjunctive therapies aimed at slowing axial elongation in children and adolescents.
• Ophthalmic anti-infective and anti-inflammatory agents: topical antibiotics, antivirals, corticosteroids and NSAID eye drops.
• Artificial tears and lubricants: formulations for dry eye and ocular surface protection across mild-to-severe presentations.
• Pipeline emphasis: innovation in long-acting ocular formulations, pediatric-friendly dosing, and registration for broader international markets.

Selected Operational & Financial Metrics

Strategic Priorities Linked to Mission & Vision

• Scale myopia-prevention portfolio through clinical trials, pediatric labeling and expanded distribution channels.
• Invest in formulation technology and GMP upgrades to support international registrations.
• Increase R&D intensity to ~10% of revenue over the medium term to accelerate pipeline maturation.
• Pursue partnerships with academic ophthalmology centers for translational research and real-world evidence generation.

Shenyang Xingqi Pharmaceutical Co.,Ltd (300573.SZ) - Overview

• Mission Statement: Dedicated to promoting health and improving vision; operationalized as 'manage health and create light.'
• Core Principles: Perseverance, innovation, responsibility, and win‑win partnerships guide product development and commercialization.
• Regulatory Compliance: Full adherence to National Medical Products Administration (NMPA) standards and international quality frameworks (GMP, ISO where applicable).

• R&D Commitment: Targets roughly 10% of total revenue for research and development focused on ophthalmic therapeutics, drug delivery systems, and formulation innovation.
• Corporate Social Responsibility: Invested over 20 million CNY in the past year on health education, community eye-care screening programs, and wellness outreach.

• Innovation Pipeline: Ongoing clinical development programs and formulation upgrades prioritized by therapeutic impact and market need.
• Quality & Safety: Manufacturing sites operate under strict process controls and batch traceability to meet domestic and export requirements.
• Stakeholder Orientation: Seeks mutually beneficial partnerships with hospitals, distributors, and research institutions to scale access to ophthalmic care.

Shenyang Xingqi Pharmaceutical Co.,Ltd (300573.SZ) - Mission Statement

• Become a globally competitive ophthalmic medication researcher and manufacturer, advancing from domestic leadership to international presence.
• Drive high-quality enterprise development through superior Party building and governance structures to ensure ethical, compliant, and effective corporate stewardship.
• Create long-term value for customers, employees, shareholders, partners, and society via sustained innovation, quality assurance, and inclusive growth.
• Continuously improve processes and technologies to promote the advancement and global recognition of Chinese national medicine in ophthalmology.
• Focus on building a leading domestic brand in ophthalmic pharmaceuticals and medical supplies with scalable global competitiveness.

• Innovation: raise R&D intensity to ~8% of revenue within three years, focusing on novel ophthalmic formulations and delivery systems.
• Quality & Compliance: achieve full GMP certification coverage across manufacturing lines and reduce product nonconformity rates by 40% vs. 2023 baseline.
• Brand & Market Expansion: increase domestic market share in prescription ophthalmic drugs and expand international distribution to account for 25% of sales within five years.
• Talent & Governance: strengthen Party-led governance while investing in talent pipelines-targeting a 20% increase in clinical and R&D headcount by 2026.
• Social Value: scale patient access programs to benefit an estimated additional 200,000 patients annually through discounted products and cooperative healthcare initiatives.

• Scale clinical pipelines in ophthalmology and accelerate filings in major regulatory jurisdictions.
• Invest in manufacturing modernization to expand capacity for sterile ophthalmic products and improve yield.
• Deepen Party-building programs to align corporate culture with high-quality development and stakeholder accountability.
• Forge strategic partnerships with international distributors and research institutions to boost global competitiveness.

Shenyang Xingqi Pharmaceutical Co.,Ltd (300573.SZ) Vision Statement

• Perseverance: sustained investment in R&D and continuous improvement in quality systems.
• Innovation: focus on new formulations, biologics discovery and process optimization.
• Responsibility: adherence to GMP, supply-chain safety, and environmental management.
• Win-win benefits: aligning shareholder returns with patient access and partner growth.
• Integrity and transparency: full compliance with disclosure, audits, and ethical conduct.
• Cooperation and tolerance: cross-functional teams, external partnerships, and inclusive culture.

• Increase R&D intensity to 5%+ of revenue within three years to drive innovative product pipelines.
• Strengthen compliance and ESG reporting-targeting reductions in emissions and waste year-over-year.
• Expand domestic and selected international distribution channels to improve patient access and scale.
• Deepen collaborative partnerships with universities, contract manufacturers, and biotech firms.
• Implement talent and culture programs that reward integrity, collaboration, and inclusive leadership.